Emerging Evidence of BRAFV600E in LCH: The Iranian Experience
نویسندگان
1 Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2 Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3 Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4 Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. - Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
6 Pediatric Nephrology Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
7 Pediatric Pathology Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8 Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran. Iran.
9 Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
10 Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
doi
10.61186/ijbc.17.1.13چکیده
Introduction: Langerhans cell histiocytosis (LCH) is an inflammatory neoplasm of myeloid origin. The pathologic CD1a+/CD207+ cells are characterized when mutations in the mitogen-activated protein kinase (MAPK) pathway (particularly in BRAFV600E) are activated and involvement of pulmonary, skeletal, pituitary, and cutaneous is seen. we aimed to evaluate a cohort of pediatric LCH ...
